Company profile
Barinthus Biotherapeutics plc.
NASDAQ:BRNSBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| NIVOLUMAB | phase2 | — | 221 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03277456 | — | completed | 2017-09-18 | 2017-11-02 | Barinthus Biotherapeutics | A Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine MVA-NP+M1 |
| NCT03880474 | phase2 | terminated | 2019-03-18 | 2019-10-15 | Barinthus Biotherapeutics | Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults |
| NCT03883113 | phase2 | completed | 2019-06-03 | 2019-12-16 | Barinthus Biotherapeutics | Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model |
| NCT05343481 | phase2 | completed | 2022-09-21 | 2026-01-13 | Barinthus Biotherapeutics | Efficacy of VTP-300 in Chronic Hepatitis B Infection |
| NCT04297917 | phase1 | completed | 2019-02-10 | 2022-05-23 | Barinthus Biotherapeutics | First in Human Study of ChAdOx1-HBV in Healthy Participants and Participants With Chronic hepB Infection |
FDA applications (0)
No records yet.